4.09
+0.16(+4.07%)
Currency In USD
| Previous Close | 3.93 |
| Open | 3.8 |
| Day High | 4.18 |
| Day Low | 3.71 |
| 52-Week High | 4.18 |
| 52-Week Low | 0.4 |
| Volume | 4.66M |
| Average Volume | 3.82M |
| Market Cap | 674.49M |
| PE | 8.18 |
| EPS | 0.5 |
| Moving Average 50 Days | 2.79 |
| Moving Average 200 Days | 1.81 |
| Change | 0.16 |
If you invested $1000 in CytomX Therapeutics, Inc. (CTMX) 10 years ago, it would be worth $385.12 as of November 05, 2025 at a share price of $4.09. Whereas If you bought $1000 worth of CytomX Therapeutics, Inc. (CTMX) shares 5 years ago, it would be worth $578.5 as of November 05, 2025 at a share price of $4.09.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
GlobeNewswire Inc.
Yesterday at 2:15 PM GMT
- CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma - - Data supportive of CX-801’s mechanism of action and the ongoing Phase 1 combination study with
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
GlobeNewswire Inc.
Oct 30, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thur
CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer
GlobeNewswire Inc.
Oct 20, 2025 8:05 PM GMT
Leadership team addition to drive strategic long-term value creation and partnering strategySOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally acti